Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INS1202 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Participants with sporadic amyotrophic lateral sclerosis (sALS) will be administered INS1202, IT injection at dose level 1 on Day 1. |
| Cohort 2 | EXPERIMENTAL | Participants with either sALS or SOD1-ALS, will be administered INS1202 via IT injection at dose level 2 on Day 1. |
| Cohort 3 | EXPERIMENTAL | Participants with either sALS or SOD1-ALS, will be administered INS1202 via IT injection at dose level 3 on Day 1. |
| Name | Type | Description |
|---|---|---|
| INS1202 | GENETIC | Suspension for injection. |
Key Inclusion Criteria: - * Participant with body mass index (BMI) ≥18 kilograms per square meter (kg/m\^2). * Participant with symptomatic ALS as diagnosed by Gold Coast diagnostic criteria. * Sporadic ALS cohorts: Negative testing for known monogenic mutations associated with familial ALS. * SOD1...
INS1202 is an investigational gene therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. It is administered as a single intrathecal injection and is currently in Phase 1 clinical development.
INS1202 targets the SOD1 gene, which is implicated in certain forms of amyotrophic lateral sclerosis. By targeting this gene, the therapy aims to address the underlying genetic component of the disease. It is delivered via intrathecal injection to reach the central nervous system.
INS1202 is being developed by Insmed Incorporated, a biopharmaceutical company. The company is conducting a Phase 1 clinical trial to evaluate the safety and pharmacodynamics of the therapy in participants with amyotrophic lateral sclerosis.
INS1202 is in Phase 1 clinical development. It is an investigational gene therapy and has not been approved by regulatory authorities. A Phase 1 trial is currently recruiting participants to assess its safety and pharmacodynamics in patients with amyotrophic lateral sclerosis.
INS1202 is being studied in a Phase 1 clinical trial with the identifier NCT07290062. This open-label, controlled study is investigating the safety and pharmacodynamics of a single intrathecal injection of INS1202 in participants with amyotrophic lateral sclerosis. The trial is recruiting 23 participants in the United States.